Tagged with HE

Opinion Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which…

USA Carla Smith outlines the role that a value-based care (VBC) approach can have on both reducing healthcare costs and improving overall care delivery to patients in the USA. Smith highlights VBC’s benefits to patients, payers and pharma companies, but notes that physicians are still not necessarily convinced; meaning the adoption…

Alzheimer's Alzheimer’s drugs represent a high-risk, high-reward proposition for global pharma. As David H. Crean recently wrote for PharmaBoardroom, “Except for one good piece of news in 2014 — for a dementia drug, Namzaric — there’s nothing by way of an FDA approval going back to 2002, 17 years of failure…

Opinion David H. Crean highlights R&D efforts and ongoing investments in Alzheimer’s disease treatments as we enter the month of June, brain awareness month.   Alzheimer’s disease is a complex chronic disease characterized biologically by the accumulation of extracellular protein plaques, neurofibrillary protein tangles, a loss of functional synaptic connections, and eventually…

Taiwan Taiwan boasts one of the most sophisticated and comprehensive public health systems in Asia. However, mounting costs and the pressures of a rapidly ageing population mean that the National Health Insurance (NHI) system may run out of money within the next two years without significant reform.   NHI expenditures have…

Spain Jaime Vives, managing director of Roche Diagnostics in Spain, discusses the digital solutions Roche Diagnostics is trying to roll out in Spain, the challenges involved, and the potential implications of digitalising healthcare   The first step into digitalization is to convince our customers to standardise their systems and the way…

Algeria Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, examines Algeria’s recent issues around medicine shortages, its root causes, and the measure being taken to counter it.   The smooth operation of the drug distribution chain in Algeria is compromised by its multiplicity of actors – from…

China Better known for its panda sanctuary and spicy local cuisine, Chengdu could be the first Chinese city to offer mutual health insurance. Eric Bouteiller examines French firm VYV’s first steps into China and the potential impact of mutual insurance – whereby the insurance company is owned entirely by its policyholders…

Egypt Dr Mohamed Mabrouk, CEO of Pharmed Healthcare, highlights how the company has evolved from only offering Hepatitis C treatment to having 112 products in the pipeline today. He also emphasises the importance of local companies for the government’s 100 Million Seha campaign, while outlining Pharmed’s future strategy including commercial partnerships…

Sweden Cardiovascular diseases are the leading cause of death among both men and women in Sweden, followed by cancer and diseases of the nervous system.   Made with Visme Infographic Maker  

Egypt The 100 Million Seha (100 Million healthy lives) campaign, which kicked off on a national scale in October 2018 under the auspices of President Abdel Fattah El-Sisi, aims to detect and eliminate Hepatitis C in Egypt by 2023. The ground-breaking initiative, organized by the Ministry of Health and Population, has…

Opinion Aditya Bhattacharji examines whether current healthcare models are truly fit for purpose and how healthcare is becoming a more politicised issue globally.   Globally, the healthcare sector is entering a lengthy period of heightened introspection. That process has been turbocharged by the resurgence of healthcare as a dominant social and…